A Phase 3 interventional study of Esketamine 28 mg and Esketamine 56 mg in Depressive Disorder, Major, sponsored by Janssen-Cilag International NV. Completed at 171 sites in 24 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2025-04-29.
Sponsored by Janssen-Cilag International NV (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing esketamine in Depressive Disorder, Major — 5 open to participants now, 5 under way, 2 of them phase 3. Esketamine · Depressive Disorder, Major.
Among the 17 studies testing esketamine in Depressive Disorder, Major, this one has the largest enrollment, is one of 3 that started in 2020, is one of 7 in phase 3, and was the 7th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →5 of the 17 studies testing esketamine in Depressive Disorder, Major are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States, Brazil, Hungary and 4 more countries
Ages 12–17
Dr. Inge Winter · Sites in Austria, Germany, Greece and 3 more countries
Ages 18–65
Royal North Shore Hospital · Sites in Australia
Ages 18–65
Massachusetts General Hospital · Sites in United States
Ages 18–70
Medical University of Vienna · Sites in Austria
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
Esketamine: first FDA approval 2019 (SPRAVATO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 676 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 147 across the 17 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 17 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen-Cilag International NV, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen-Cilag International NV is the lead sponsor of 67 studies on the registry; none are open to participants now.
59 studies in Depressive Disorder, Major by Johnson & Johnson: 5 open now, 5 under way, 5 of them phase 3. Of 53 finished, 26 (49%) have results posted.
Among the 59 studies in Depressive Disorder, Major by Johnson & Johnson, this one is the 5th largest by enrollment of the 52 interventional ones that give a count, is one of 7 that started in 2020, is one of 23 in phase 3, and was the 34th registered.
Johnson & Johnson’s Depressive Disorder, Major studies by the year they started, since 2002.
1 of the studies testing esketamine in Depressive Disorder, Major that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05450432Massachusetts General HospitalLong-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing esketamine in Depressive Disorder, Major, from their registry updates:
Among Johnson & Johnson’s 59 in Depressive Disorder, Major:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to evaluate the efficacy of flexibly dosed esketamine nasal spray compared with quetiapine extended-release (XR), both in combination with a continuing selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI), in achieving remission in participants who have treatment-resistant major depressive disorder (MDD) with a current moderate to severe depressive episode.
A depressive state with classical symptoms such as low (depressive/sad) mood, markedly diminished interest in activities, significant weight loss/gain, insomnia or hypersomnia, psychomotor agitation/retardation, excessive fatigue, inappropriate guilt, diminished concentration, and recurrent thoughts of death, persisting for more than 2 weeks is classified as major depressive disorder (MDD). The mechanism of action of ketamine is distinct from conventional antidepressants (ADs), which target the monoamines (serotonin, norepinephrine, and/or dopamine). Esketamine, the S-enantiomer of ketamine, is approved and widely used for the induction and maintenance of anesthesia via intramuscular or intravenous (IV) administration. There is a significant unmet need to develop novel AD treatments based on the relevant psychophysiological pathways underlying MDD. The goal of any novel treatment would be the rapid and long-lasting relief of depressive symptoms, especially in participants with treatment-resistant depression (TRD), who lack a sufficient response to the currently available treatment strategies. The study consists of a Screening Phase (up to 14 days), an Acute Phase (8 Weeks), a Maintenance Phase (24 Weeks) and a Safety Follow-up Phase (2 Weeks). Safety assessment includes adverse event, serious adverse events, physical examination, vital signs, electrocardiogram, clinical safety laboratory assessments, suicidal risk monitoring. The total duration of the study is approximately 36 Weeks for all participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive treatment with esketamine nasal spray (28 milligram \[mg\] \[initial dose for elderly participants 65 to 74 years of age and adults of Japanese ancestry; may be used throughout the study in these populations; may be uptitrated in 28 mg increments\], 56 mg \[initial dose for adult participants aged 18 to 64 years and may be used for all age groups throughout the study\], or 84 mg \[maximum dose esketamine nasal spray may be uptitrated to\]) twice-weekly with a flexible dose regimen from Day 1 until Week 4, once weekly from Week 5 to Week 8 and once-weekly or once every 2 weeks from Week 9 to Week 32 in combination with continuing serotonin-norepinephrine reuptake inhibitor/selective serotonin reuptake inhibitor (SSRI/SNRI).
Drug: Esketamine 28 mg · Drug: Esketamine 56 mg · Drug: Esketamine 84 mg · Drug: SSRI/SNRI
Participants will continue to take their current SSRI/SNRI augmented with quetiapine extended release (XR) as per the Summary of Product Characteristics (SmPC) (or local equivalent, if applicable). In adult participants aged 18 to 64 years, the initial dose is 50 mg/day on Days 1-2, 150 mg/day on Days 3-4 \[lowest effective dose\]; a further dose increase to 300 mg/day on Day 5 and onward will be based on individual participant evaluation. In elderly participants aged 65 to 74 years, the initial dose is 50 mg/day on Days 1-3, 100 mg/day on Days 4-7, and 150 mg/day on Day 8; a further dose increase to 300 mg/day will be based on individual participant evaluation no earlier than Day 22.
Drug: Quetiapine XR 50 mg · Drug: Quetiapine XR 100 mg · Drug: Quetiapine XR 150 mg · Drug: SSRI/SNRI
Esketamine will be self-administered at a dose of 28 mg as nasal spray.
Esketamine will be self-administered at a dose of 56 mg as nasal spray.
Esketamine will be self-administered at a dose of 84 mg (maximum uptitrated dose) as nasal spray.
Quetiapine XR will be administered at an initial dose of 50 mg/day and may be further increased to 300 mg/day based on individual participant evaluation.
Quetiapine XR will be administered at a dose of 100 mg/day and may be further increased to 300 mg/day based on individual participant evaluation.
Quetiapine XR will be administered at a dose of 150 mg/day and may be further increased to 300 mg/day based on individual participant evaluation.
Participants will continue to take SSRI/SNRI that is approved for use in depression in their country of participation; off-label use of any SSRI/SNRI is not permitted. The continuing SSRI/SNRI dosage may be optimized throughout the study, at the investigator's discretion and based on the SmPC (or local equivalent, if applicable).
Percentage of Participants With Remission as Assessed by the Montgomery-Asberg Depression Rating Scale (MADRS) Score at Week 8
Percentage of participants with remission as assessed by the MADRS at Week 8 was reported. The MADRS is a clinician-rated scale designed to measure depression severity and to detect changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition. The MADRS evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts. A participant was defined as being in remission if the MADRS total score was less than or equal to (\<=)10 and no treatment or study discontinuation before Week 8.
Time frame: Week 8
Percentage of Participants With Both Remission at Week 8 and Relapse-free Until Week 32
Percentage of participants with both remission at Week 8 and relapse-free until Week 32 were reported. A participant was defined as being in remission if the MADRS total score was \<= 10 and no treatment or study discontinuation before Week 8. A relapse was defined by any of following: a) Worsening of depressive symptoms as indicated by MADRS total score greater than or equal to (\>=) 22 confirmed by 1 additional assessment of MADRS total score \>= 22 within the next 5 to 15 days. The date of the second MADRS assessment was used for the date of relapse; b) Any psychiatric hospitalization for: worsening of depression, suicide prevention or suicide attempt, the start date of hospitalization was the date of relapse; c) Suicide attempt, completed suicide, or any other clinically relevant event determined by investigator's judgment to be indicative of a relapse of depressive illness, but without hospitalized. The onset of the event was used for the date of relapse.
Time frame: Week 32
Change From Baseline in Clinician-rated Overall MADRS Score
Change from baseline in clinician-rated overall MADRS score was reported. The MADRS is a clinician-rated scale designed to measure depression severity and to detect changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptoms), summed up for a total possible score range of 0 to 60. Higher scores represent a more severe condition. The MADRS evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts.
Time frame: Baseline, Weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32
Change From Baseline in Clinician-rated Overall MADRS Score at Last Observation Carried Forward (LOCF)
Change from baseline in clinician-rated overall MADRS score at LOCF was reported. The MADRS is a clinician-rated scale designed to measure depression severity and to detect changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptoms), summed up for a total possible score range of 0 to 60. Higher scores represent a more severe condition. The MADRS evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts. LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.
Time frame: Baseline, LOCF at Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32
Change From Baseline in Clinician-rated Overall Severity of Depressive Illness as Assessed by Clinical Global Impression - Severity (CGI-S) Scale Score
Change from baseline in clinician-rated overall severity of depressive illness as assessed by CGI-S scale score was reported. The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluates the severity of psychopathology on a scale of 1 to 7. Considering total clinical experience, a participant is assessed on severity of mental illness at the time of rating according to: 1 = normal (not at all ill); 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. Negative change in score indicates improvement.
Time frame: Baseline, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32
Change From Baseline in Clinician-rated Overall Severity of Depressive Illness as Assessed by CGI-S Scale Score at LOCF
Change from Baseline in clinician-rated overall severity of depressive illness as assessed by CGI-S scale score at LOCF was reported. The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluates the severity of psychopathology on a scale of 1 to 7. A participant is assessed on severity of mental illness at the time of rating according to: 1 = normal (not at all ill); 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.
Time frame: Baseline, LOCF at Weeks 2, 3, 4, 8, 12, 16, 20, 24, 28, 32
Clinician-rated Overall Severity of Depressive Illness as Assessed by Clinical Global Impression - Change (CGI-C) Scale Score
Clinician-rated overall severity of depressive illness as assessed by CGI-C scale score was reported. The CGI-C evaluates the total improvement whether or not entirely due to drug treatment on a scale of 1 to 7. Compared to the condition at baseline, a participant is assessed on how much he/she has changed, according to: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse. Higher scores indicate more severity.
Time frame: Baseline, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32
Number of Participants With Clinician-rated Overall Severity of Depressive Illness as Assessed by CGI-C Scale Score at LOCF
Number of participants with clinician-rated overall severity of depressive illness as assessed by CGI-C scale score at LOCF was reported. The CGI-C evaluates the total improvement whether or not entirely due to drug treatment on a scale of 1 to 7. Compared to the condition at baseline, a participant is assessed on how much he/she has changed, according to: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse. Higher scores indicate more severity. LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.
Time frame: Baseline, LOCF at Weeks 2, 3, 4, 8, 12, 16, 20, 24, 28, 32
Change From Baseline in Participant-reported Depressive Symptoms as Assessed by Patient Health Questionnaire (PHQ) 9-item Total Score
Change from baseline in participant-reported depressive symptoms as assessed by PHQ 9-item total score was reported. The PHQ-9 is a validated 9-item, patient-reported outcome (PRO) measure to assess depressive symptoms. Each item is rated on a 4-point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 is categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19) and Severe (20-27).
Time frame: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32
Change From Baseline in Participant-reported Depressive Symptoms as Assessed by PHQ 9-item Total Score at LOCF
Change from baseline in participant-reported depressive symptoms as assessed by PHQ 9-item total score at LOCF was reported. The PHQ-9 is a validated 9-item, PRO measure to assess depressive symptoms. Each item is rated on a 4-point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 is categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19) and Severe (20-27). LOCF is defined as participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.
Time frame: Baseline, LOCF at Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32
Change From Baseline in Participant-reported Functional Impairment and Associated Disability as Assessed by Sheehan Disability Scale (SDS) Total Score
Change from baseline in participant-reported functional impairment and associated disability as assessed by SDS total score was reported. The SDS is a validated PRO measure consisting of a 5-item questionnaire that has been widely used and accepted for assessment of functional impairment and associated disability. The first 3 items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a rating scale from 0 to 10. It also has 1 item assessing days lost from school or work and 1 item assessing days of underproductivity. The scores for the first 3 items are summed to create a total score of 0 to 30, where higher score indicates greater impairment. Scores \<=2 for each item and \<= 6 for the total score are considered functional remission.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32
Change From Baseline in Participant-reported Functional Impairment and Associated Disability as Assessed by SDS Total Score at LOCF
Change from baseline in participant-reported functional impairment and associated disability as assessed by SDS total score at LOCF was reported. The SDS is a validated PRO measure consisting of a 5-item questionnaire for assessment of functional impairment and associated disability. The first 3 items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a rating scale from 0 to 10. It also has 1 item assessing days lost from school or work and 1 item assessing days of underproductivity. The scores for the first 3 items are summed to create a total score of 0 to 30, where higher score indicates greater impairment. Scores \<=2 for each item and \<= 6 for the total score are considered functional remission. LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.
Time frame: Baseline, LOCF at Weeks 4, 8, 12, 16, 20, 24, 28, 32
Change From Baseline in Participant-reported Health-related Quality of Life (HRQoL) and Health Status as Assessed by 36-item Short-Form Health Survey (SF-36) Scale Score
Change from baseline in participant-reported HRQoL and health status as assessed by SF-36 scale score was reported. The SF-36 consists of 8 subscales (physical function, role limitations due to physical problems, pain, general health perception, vitality, social function, role limitations due to emotional problems, and mental health). Participants self-report on items in a subscale that have between 2-6 choices per item using likert-type responses (for example: none of the time, some of the time, etc.). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100; 0= worst HRQoL, 100=best HRQoL. Higher scores indicate better health status.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32
Change From Baseline in Participant-reported HRQoL and Health Status as Assessed by SF-36 Scale Score at LOCF
Change from baseline in participant-reported HRQoL and health status as assessed by SF-36 domain scores at LOCF was reported. The SF-36 consists of 8 subscales (physical function, role limitations due to physical problems, pain, general health perception, vitality, social function, role limitations due to emotional problems, and mental health). Participants self-report on items in a subscale that have between 2-6 choices per item using likert-type responses (for example: none of the time, some of the time, etc.). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100; 0= worst HRQoL, 100=best HRQoL. Higher scores indicate better health status. LOCF is defined as participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.
Time frame: Baseline, LOCF at Weeks 8, 12, 16, 20, 24, 28, 32
Change From Baseline in Participant-reported Quality of Life as Assessed by Quality of Life in Depression Scale (QLDS) Total Score
Change from baseline in participant-reported quality of life as assessed by QLDS total score was reported. The QLDS is a disease-specific validated PRO measure which assesses the impact that depression has on a participant's quality of life. It is a 34-item self-rated questionnaire which consists of dichotomous response questions, with the response being either True/Not True. Each statement on the QLDS is given a score of "1" or "0". A score of "1" is indicative of adverse quality of life. All item scores are summed to give a total score that ranges from 0 (good quality of life) to 34 (very poor quality of life). A higher score indicates a more severe condition.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32
Change From Baseline in Participant-reported Quality of Life as Assessed by QLDS Total Score at LOCF
Change from baseline in participant-reported quality of life as assessed by QLDS total score at LOCF was reported. The QLDS is a disease-specific validated PRO measure which assesses the impact that depression has on a participant's quality of life. It is a 34-item self-rated questionnaire which consists of dichotomous response questions, with the response being either True/Not True. Each statement on the QLDS is given a score of "1" or "0". A score of "1" is indicative of adverse quality of life. All item scores are summed to give a total score that ranges from 0 (good quality of life) to 34 (very poor quality of life). A higher score indicates a more severe condition. LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.
Time frame: Baseline, LOCF at Weeks 4, 8, 12, 16, 20, 24, 28, 32
Change From Baseline in Participant-reported Health-related Quality of Life as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) Score: Health Status Index
Change from baseline in participant-reported health-related quality of Life as assessed by EQ-5D-5L score: health status index was reported. The EQ-5D-5L is a standardized 2-part instrument used to measure health outcomes, primarily designed for self-completion by respondents. It consists of the EQ-5D-5L descriptive system and the EQ Visual Analogue Scale (EQ-VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions is divided into 5 levels of perceived problems (level 1 = no problem, level 2 = slight problems, level 3 = moderate problems, level 4 = severe problems, level 5 = extreme problems). The participant selects an answer for each of the 5 dimensions considering the response that best matches his or her health "today." Responses were used to generate health status index which ranges from 0 (dead) and 1 (full health), a lower score indicates worse health.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32
Change From Baseline in Participant-reported Health-related Quality of Life Group, as Assessed by EQ-5D-5L Score: Health Status Index at LOCF
Change from baseline in participant-reported health-related quality of Life as assessed by EQ-5D-5L score: health status index at LOCF was reported. The EQ-5D-5L is a standardized 2-part instrument used to measure health outcomes, primarily designed for self-completion by respondents. It consists of the EQ-5D-5L descriptive system and the EQ-VAS. The EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions is divided into 5 levels of perceived problems (level 1 = no problem, level 2 = slight problems, level 3 = moderate problems, level 4 = severe problems, level 5 = extreme problems). The participant selects an answer for each of the 5 dimensions considering the response that best matches his or her health "today." LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.
Time frame: Baseline, LOCF at Weeks 4, 8, 12, 16, 20, 24, 28, 32
Change From Baseline in Participant-reported Health Status as Assessed by EQ-5D-5L Score: VAS
Change from baseline in participant-reported health status as assessed by EQ-5D-5L Score: VAS was reported. The EQ-5D-5L is a standardized 2-part instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. It essentially consists of the EQ-5D-5L descriptive system and the EQ-VAS. EQ-VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Positive change in score indicates improvement.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32
Change From Baseline in Participant-reported Health Status as Assessed by EQ-5D-5L Score: VAS at LOCF
Change from baseline in participant-reported health status as assessed by EQ-5D-5L score: VAS at LOCF was reported. The EQ-5D-5L is a standardized 2-part instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. It essentially consists of the EQ-5D-5L descriptive system and the EQ-VAS. EQ-VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Positive change in score indicates improvement. LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.
Time frame: Baseline, LOCF at Weeks 4, 8, 12, 16, 20, 24, 28, 32
Change From Baseline in Participant-reported Work Productivity as Assessed by Work Productivity and Activity Impairment (WPAI): Depression Questionnaire
Change from baseline in participant-reported work productivity as assessed by WPAI: depression questionnaire was reported. The WPAI-D questionnaire is a validated short instrument that assesses impairment in work and other regular activities over the past 7 days. The WPAI yields four types of scores: (a) Absenteeism (work time missed); (b) Presenteeism (impairment at work / reduced on-the-job effectiveness); (c) Work productivity loss (overall work impairment / absenteeism plus presenteeism); (d) Activity Impairment. The first three scores were derived only for respondents who were working (should be missing for non-working), but the last score was applicable for all respondents. Each score ranges from 0 to 100 with higher scores indicating greater impairment and less productivity.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32
Change From Baseline in Participant-reported Work Productivity as Assessed by WPAI: Depression Questionnaire at LOCF
Change from baseline in participant-reported work productivity as assessed by WPAI: depression questionnaire at LOCF was reported. The WPAI-D questionnaire is a validated short instrument that assesses impairment in work and other regular activities over the past 7 days. The WPAI yields four types of scores: (a) Absenteeism (work time missed); (b) Presenteeism (impairment at work / reduced on-the-job effectiveness); (c) Work productivity loss (overall work impairment / absenteeism plus presenteeism); (d) Activity Impairment. The first three scores were derived only for respondents who were working (should be missing for non-working), but the last score was applicable for all respondents. Each score ranges from 0 to 100 with higher scores indicating greater impairment and less productivity. LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.
Time frame: Baseline, LOCF at Weeks 4, 8, 12, 16, 20, 24, 28, 32
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. TEAEs were those events if they started after administration of the first dose until 14 days after the last dose of study medication for other TEAEs except serious; and first dose until 30 days after the last dose of study medication for serious TEAEs.
Time frame: Up to Week 35
Number of Participants With TEAEs of Special Interest
Number of participants with TEAEs of special interest were reported. It included significant TEAEs that were judged to be of special interest because of clinical importance, known or suspected class effects, or based on nonclinical signals. Events such as sedation, depersonalization/derealization disorder, depression suicidal, aggression, allergic cystitis, cholestasis and jaundice of hepatic origin, and many more were considered as TEAEs of special interest.
Time frame: Up to Week 35
Number of Participants With Suicidal Ideation or Behavior as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) Score
Number of participants with suicidal ideation or behavior as assessed by C-SSRS score was reported. The C-SSRS is an assessment tool that evaluates suicidal ideation and behavior. Suicidal ideation consists of 5 items: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intention to act, active suicidal ideation with some intent to act without specific plan, and active suicidal ideation with specific plan and intent. Suicidal behavior consists of 5 items: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt (non-fatal), and completed suicide. The maximum score (from the 10 categories) assigned for each participant was summarized into one of three broad categories: No suicidal ideation or behavior (0), Suicidal ideation (1 - 5), Suicidal behavior (6 - 10). Total score ranges from 1 to 10. Higher scores indicate more severe suicidal ideation and behavior.
Time frame: Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32
| Milestone | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD |
|---|---|---|
| Started | 336 | 340 |
| Treated (safety analysis set) | 334 | 336 |
| Completed treatment | 258 | 203 |
| Completed | 274 | 232 |
| Not completed | 62 | 108 |
| Withdrew: Adverse event | 4 | 10 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Lost to follow-up | 4 | 9 |
| Withdrew: Withdrawal by subject | 45 | 69 |
| Withdrew: Physician decision | 5 | 9 |
| Withdrew: Other | 3 | 10 |
Percentage of participants with remission as assessed by the MADRS at Week 8 was reported. The MADRS is a clinician-rated scale designed to measure depression severity and to detect changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition. The MADRS evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts. A participant was defined as being in remission if the MADRS total score was less than or equal to (\<=)10 and no treatment or study discontinuation before Week 8.
| Percentage of participants | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD |
|---|---|---|
| Percentage of Participants With Remission as Assessed by the Montgomery-Asberg Depression Rating Scale (MADRS) Score at Week 8 | 27.1 | 17.6 |
Percentage of participants with both remission at Week 8 and relapse-free until Week 32 were reported. A participant was defined as being in remission if the MADRS total score was \<= 10 and no treatment or study discontinuation before Week 8. A relapse was defined by any of following: a) Worsening of depressive symptoms as indicated by MADRS total score greater than or equal to (\>=) 22 confirmed by 1 additional assessment of MADRS total score \>= 22 within the next 5 to 15 days. The date of the second MADRS assessment was used for the date of relapse; b) Any psychiatric hospitalization for: worsening of depression, suicide prevention or suicide attempt, the start date of hospitalization was the date of relapse; c) Suicide attempt, completed suicide, or any other clinically relevant event determined by investigator's judgment to be indicative of a relapse of depressive illness, but without hospitalized. The onset of the event was used for the date of relapse.
| Percentage of Participants | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD |
|---|---|---|
| Percentage of Participants With Both Remission at Week 8 and Relapse-free Until Week 32 | 21.7 | 14.1 |
Change from baseline in clinician-rated overall MADRS score was reported. The MADRS is a clinician-rated scale designed to measure depression severity and to detect changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptoms), summed up for a total possible score range of 0 to 60. Higher scores represent a more severe condition. The MADRS evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts.
| Unit on scale | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD |
|---|---|---|
| Week 1 | -5.3 ± 5.71 | -3.7 ± 4.65 |
| Week 2 | -9.0 ± 6.87 | -6.1 ± 6.52 |
| Week 4 | -12.8 ± 7.50 | -9.8 ± 7.32 |
| Week 6 | -14.9 ± 8.27 | -12.2 ± 8.11 |
| Week 8 | -16.4 ± 8.67 | -14.3 ± 8.26 |
| Week 10 | -18.2 ± 8.32 | -16.2 ± 7.38 |
| Week 12 | -18.4 ± 8.26 | -16.7 ± 8.16 |
| Week 14 | -19.0 ± 8.06 | -17.1 ± 8.06 |
| Week 16 | -19.6 ± 8.16 | -17.8 ± 8.23 |
| Week 18 | -19.9 ± 8.59 | -18.1 ± 8.36 |
| Week 20 | -20.1 ± 8.75 | -19.1 ± 8.11 |
| Week 22 | -20.6 ± 8.32 | -19.5 ± 8.04 |
| Week 24 | -21.0 ± 8.58 | -20.1 ± 7.96 |
| Week 26 | -21.2 ± 8.19 | -20.0 ± 8.18 |
| Week 28 | -21.5 ± 8.33 | -20.8 ± 8.33 |
| Week 30 | -21.8 ± 8.66 | -20.6 ± 8.39 |
| Week 32 | -22.2 ± 8.12 | -20.5 ± 8.58 |
Change from baseline in clinician-rated overall MADRS score at LOCF was reported. The MADRS is a clinician-rated scale designed to measure depression severity and to detect changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of the symptoms), summed up for a total possible score range of 0 to 60. Higher scores represent a more severe condition. The MADRS evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts. LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.
| Unit on scale | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD |
|---|---|---|
| Week 2 | -9.0 ± 6.86 | -5.8 ± 6.53 |
| Week 4 | -12.6 ± 7.63 | -8.9 ± 7.70 |
| Week 6 | -14.5 ± 8.47 | -10.7 ± 8.78 |
| Week 8 | -15.7 ± 9.07 | -12.0 ± 9.30 |
| Week 10 | -16.9 ± 9.15 | -12.8 ± 9.24 |
| Week 12 | -17.1 ± 9.22 | -13.1 ± 9.82 |
| Week 14 | -17.6 ± 9.08 | -13.2 ± 9.88 |
| Week 16 | -18.1 ± 9.24 | -13.7 ± 10.17 |
| Week 18 | -18.1 ± 9.60 | -13.8 ± 10.26 |
| Week 20 | -18.2 ± 9.80 | -14.3 ± 10.46 |
| Week 22 | -18.7 ± 9.83 | -14.6 ± 10.56 |
| Week 24 | -18.8 ± 9.88 | -14.8 ± 10.77 |
| Week 26 | -19.0 ± 9.76 | -14.9 ± 10.76 |
| Week 28 | -19.1 ± 9.88 | -15.2 ± 11.08 |
| Week 30 | -19.2 ± 10.10 | -15.2 ± 11.11 |
| Week 32 | -19.6 ± 9.94 | -15.1 ± 11.18 |
Change from baseline in clinician-rated overall severity of depressive illness as assessed by CGI-S scale score was reported. The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluates the severity of psychopathology on a scale of 1 to 7. Considering total clinical experience, a participant is assessed on severity of mental illness at the time of rating according to: 1 = normal (not at all ill); 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. Negative change in score indicates improvement.
| Units on scale | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD |
|---|---|---|
| Week 1 | -0.3 ± 0.58 | -0.2 ± 0.53 |
| Week 2 | -0.7 ± 0.79 | -0.5 ± 0.77 |
| Week 3 | -1.0 ± 0.88 | -0.7 ± 0.83 |
| Week 4 | -1.3 ± 0.94 | -1.0 ± 0.95 |
| Week 8 | -1.7 ± 0.98 | -1.4 ± 1.05 |
| Week 12 | -1.9 ± 1.00 | -1.7 ± 1.07 |
| Week 16 | -2.1 ± 1.05 | -1.9 ± 1.15 |
| Week 20 | -2.2 ± 1.04 | -2.0 ± 1.22 |
| Week 24 | -2.3 ± 1.06 | -2.1 ± 1.22 |
| Week 28 | -2.4 ± 1.02 | -2.2 ± 1.19 |
| Week 32 | -2.5 ± 1.05 | -2.3 ± 1.21 |
Change from Baseline in clinician-rated overall severity of depressive illness as assessed by CGI-S scale score at LOCF was reported. The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluates the severity of psychopathology on a scale of 1 to 7. A participant is assessed on severity of mental illness at the time of rating according to: 1 = normal (not at all ill); 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.
| Units on scale | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD |
|---|---|---|
| Week 2 | -0.7 ± 0.79 | -0.5 ± 0.75 |
| Week 3 | -1.0 ± 0.88 | -0.7 ± 0.84 |
| Week 4 | -1.3 ± 0.95 | -0.9 ± 0.96 |
| Week 8 | -1.6 ± 1.02 | -1.2 ± 1.10 |
| Week 12 | -1.8 ± 1.09 | -1.3 ± 1.18 |
| Week 16 | -1.9 ± 1.16 | -1.4 ± 1.26 |
| Week 20 | -2.0 ± 1.17 | -1.5 ± 1.32 |
| Week 24 | -2.1 ± 1.22 | -1.5 ± 1.35 |
| Week 28 | -2.1 ± 1.22 | -1.6 ± 1.36 |
| Week 32 | -2.2 ± 1.27 | -1.6 ± 1.40 |
Clinician-rated overall severity of depressive illness as assessed by CGI-C scale score was reported. The CGI-C evaluates the total improvement whether or not entirely due to drug treatment on a scale of 1 to 7. Compared to the condition at baseline, a participant is assessed on how much he/she has changed, according to: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse. Higher scores indicate more severity.
| Units on scale | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD |
|---|---|---|
| Week 1 | 3.3 ± 0.77 | 3.6 ± 0.72 |
| Week 2 | 2.9 ± 0.87 | 3.3 ± 0.85 |
| Week 3 | 2.7 ± 0.83 | 3.1 ± 0.84 |
| Week 4 | 2.4 ± 0.85 | 2.9 ± 0.96 |
| Week 8 | 2.1 ± 0.84 | 2.4 ± 0.93 |
| Week 12 | 2.0 ± 0.85 | 2.3 ± 0.89 |
| Week 16 | 1.9 ± 0.87 | 2.2 ± 0.99 |
| Week 20 | 1.8 ± 0.85 | 2.1 ± 0.92 |
| Week 24 | 1.8 ± 0.85 | 2.0 ± 0.84 |
| Week 28 | 1.7 ± 0.84 | 2.0 ± 0.91 |
| Week 32 | 1.6 ± 0.81 | 1.9 ± 0.88 |
Number of participants with clinician-rated overall severity of depressive illness as assessed by CGI-C scale score at LOCF was reported. The CGI-C evaluates the total improvement whether or not entirely due to drug treatment on a scale of 1 to 7. Compared to the condition at baseline, a participant is assessed on how much he/she has changed, according to: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; 7 = very much worse. Higher scores indicate more severity. LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.
| Participants | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD |
|---|---|---|
| Very much improved at Week 2 | 6 | 4 |
| Much improved at Week 2 | 97 | 39 |
| Minimally improved at Week 2 | 141 | 149 |
| No change at Week 2 | 75 | 108 |
| Minimally worse at Week 2 | 6 | 26 |
| Much worse at Week 2 | 1 | 5 |
| Very much worse at Week 2 | 1 | 0 |
| Very much improved at Week 3 | 14 | 8 |
| Much improved at Week 3 | 126 | 57 |
| Minimally improved at Week 3 | 135 | 159 |
| No change at Week 3 | 45 | 81 |
| Minimally worse at Week 3 | 6 | 20 |
| Much worse at Week 3 | 0 | 6 |
| Very much worse at Week 3 | 1 | 0 |
| Very much improved at Week 4 | 41 | 17 |
| Much improved at Week 4 | 150 | 83 |
| Minimally improved at Week 4 | 102 | 152 |
| No change at Week 4 | 29 | 52 |
| Minimally worse at Week 4 | 4 | 17 |
| Much worse at Week 4 | 0 | 10 |
| Very much worse at Week 4 | 1 | 0 |
| Very much improved at Week 8 | 68 | 38 |
| Much improved at Week 8 | 165 | 118 |
| Minimally improved at Week 8 | 68 | 105 |
| No change at Week 8 | 18 | 44 |
| Minimally worse at Week 8 | 5 | 16 |
| Much worse at Week 8 | 2 | 10 |
| Very much worse at Week 8 | 1 | 0 |
| Very much improved at Week 12 | 83 | 45 |
| Much improved at Week 12 | 156 | 120 |
| Minimally improved at Week 12 | 53 | 92 |
| No change at Week 12 | 24 | 47 |
| Minimally worse at Week 12 | 9 | 18 |
| Much worse at Week 12 | 1 | 9 |
| Very much worse at Week 12 | 1 | 0 |
| Very much improved at Week 16 | 100 | 55 |
| Much improved at Week 16 | 136 | 111 |
| Minimally improved at Week 16 | 58 | 84 |
| No change at Week 16 | 25 | 49 |
| Minimally worse at Week 16 | 5 | 23 |
| Much worse at Week 16 | 2 | 9 |
| Very much worse at Week 16 | 1 | 0 |
| Very much improved at Week 20 | 106 | 61 |
| Much improved at Week 20 | 137 | 110 |
| Minimally improved at Week 20 | 55 | 83 |
| No change at Week 20 | 19 | 49 |
| Minimally worse at Week 20 | 7 | 19 |
| Much worse at Week 20 | 2 | 9 |
| Very much worse at Week 20 | 1 | 0 |
| Very much improved at Week 24 | 123 | 64 |
| Much improved at Week 24 | 123 | 109 |
| Minimally improved at Week 24 | 48 | 86 |
| No change at Week 24 | 25 | 44 |
| Minimally worse at Week 24 | 6 | 19 |
| Much worse at Week 24 | 1 | 9 |
| Very much worse at Week 24 | 1 | 0 |
| Very much improved at Week 28 | 127 | 71 |
| Much improved at Week 28 | 121 | 104 |
| Minimally improved at Week 28 | 46 | 80 |
| No change at Week 28 | 24 | 48 |
| Minimally worse at Week 28 | 7 | 19 |
| Much worse at Week 28 | 1 | 9 |
| Very much worse at Week 28 | 1 | 0 |
| Very much improved at Week 32 | 148 | 82 |
| Much improved at Week 32 | 103 | 96 |
| Minimally improved at Week 32 | 42 | 81 |
| No change at Week 32 | 28 | 43 |
| Minimally worse at Week 32 | 4 | 20 |
| Much worse at Week 32 | 1 | 9 |
| Very much worse at Week 32 | 1 | 0 |
Change from baseline in participant-reported depressive symptoms as assessed by PHQ 9-item total score was reported. The PHQ-9 is a validated 9-item, patient-reported outcome (PRO) measure to assess depressive symptoms. Each item is rated on a 4-point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 is categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19) and Severe (20-27).
| Units on scale | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD |
|---|---|---|
| Week 2 | -4.9 ± 4.90 | -3.1 ± 4.62 |
| Week 4 | -6.7 ± 5.25 | -5.0 ± 5.06 |
| Week 6 | -8.1 ± 5.37 | -6.1 ± 5.64 |
| Week 8 | -8.9 ± 5.74 | -7.4 ± 5.58 |
| Week 10 | -9.6 ± 5.37 | -8.4 ± 5.58 |
| Week 12 | -9.8 ± 5.78 | -8.7 ± 5.65 |
| Week 14 | -10.2 ± 5.49 | -8.5 ± 5.76 |
| Week 16 | -10.5 ± 5.50 | -9.2 ± 5.77 |
| Week 18 | -10.6 ± 5.79 | -9.3 ± 5.74 |
| Week 20 | -10.4 ± 5.64 | -9.4 ± 5.97 |
| Week 22 | -10.7 ± 5.74 | -9.5 ± 5.87 |
| Week 24 | -10.6 ± 5.84 | -9.7 ± 6.08 |
| Week 26 | -10.9 ± 5.88 | -9.7 ± 6.21 |
| Week 28 | -10.9 ± 6.16 | -10.0 ± 6.23 |
| Week 30 | -11.2 ± 6.39 | -10.1 ± 6.08 |
| Week 32 | -11.4 ± 6.40 | -10.5 ± 6.01 |
Change from baseline in participant-reported depressive symptoms as assessed by PHQ 9-item total score at LOCF was reported. The PHQ-9 is a validated 9-item, PRO measure to assess depressive symptoms. Each item is rated on a 4-point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 is categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19) and Severe (20-27). LOCF is defined as participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.
| Units on scale | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD |
|---|---|---|
| Week 2 | -4.9 ± 4.90 | -3.1 ± 4.62 |
| Week 4 | -6.6 ± 5.33 | -4.7 ± 5.06 |
| Week 6 | -7.8 ± 5.51 | -5.6 ± 5.69 |
| Week 8 | -8.5 ± 5.94 | -6.3 ± 5.86 |
| Week 10 | -9.0 ± 5.75 | -7.0 ± 5.90 |
| Week 12 | -9.1 ± 6.13 | -7.1 ± 6.07 |
| Week 14 | -9.3 ± 5.93 | -6.9 ± 6.12 |
| Week 16 | -9.6 ± 5.98 | -7.4 ± 6.20 |
| Week 18 | -9.5 ± 6.26 | -7.3 ± 6.21 |
| Week 20 | -9.4 ± 6.12 | -7.4 ± 6.32 |
| Week 22 | -9.7 ± 6.27 | -7.5 ± 6.31 |
| Week 24 | -9.5 ± 6.35 | -7.5 ± 6.47 |
| Week 26 | -9.7 ± 6.46 | -7.5 ± 6.56 |
| Week 28 | -9.7 ± 6.66 | -7.6 ± 6.64 |
| Week 30 | -9.9 ± 6.85 | -7.6 ± 6.61 |
| Week 32 | -10.1 ± 6.94 | -8.0 ± 6.70 |
Change from baseline in participant-reported functional impairment and associated disability as assessed by SDS total score was reported. The SDS is a validated PRO measure consisting of a 5-item questionnaire that has been widely used and accepted for assessment of functional impairment and associated disability. The first 3 items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a rating scale from 0 to 10. It also has 1 item assessing days lost from school or work and 1 item assessing days of underproductivity. The scores for the first 3 items are summed to create a total score of 0 to 30, where higher score indicates greater impairment. Scores \<=2 for each item and \<= 6 for the total score are considered functional remission.
| Units on scale | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD |
|---|---|---|
| Week 4 | -5.9 ± 6.58 | -4.1 ± 5.89 |
| Week 8 | -8.6 ± 7.03 | -6.8 ± 7.63 |
| Week 12 | -9.7 ± 7.54 | -8.6 ± 6.94 |
| Week 16 | -10.6 ± 7.29 | -9.0 ± 7.50 |
| Week 20 | -10.9 ± 7.57 | -9.0 ± 7.41 |
| Week 24 | -11.2 ± 7.88 | -10.1 ± 7.76 |
| Week 28 | -11.9 ± 7.84 | -10.8 ± 8.03 |
| Week 32 | -12.6 ± 8.09 | -11.1 ± 8.06 |
Change from baseline in participant-reported functional impairment and associated disability as assessed by SDS total score at LOCF was reported. The SDS is a validated PRO measure consisting of a 5-item questionnaire for assessment of functional impairment and associated disability. The first 3 items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a rating scale from 0 to 10. It also has 1 item assessing days lost from school or work and 1 item assessing days of underproductivity. The scores for the first 3 items are summed to create a total score of 0 to 30, where higher score indicates greater impairment. Scores \<=2 for each item and \<= 6 for the total score are considered functional remission. LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.
| Units on scale | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD |
|---|---|---|
| Week 4 | -5.9 ± 6.58 | -4.1 ± 5.89 |
| Week 8 | -8.2 ± 7.06 | -5.8 ± 7.45 |
| Week 12 | -9.0 ± 7.59 | -6.8 ± 7.59 |
| Week 16 | -9.8 ± 7.47 | -7.0 ± 7.99 |
| Week 20 | -9.9 ± 7.75 | -7.0 ± 7.97 |
| Week 24 | -10.0 ± 8.13 | -7.6 ± 8.37 |
| Week 28 | -10.4 ± 8.21 | -7.9 ± 8.69 |
| Week 32 | -11.1 ± 8.56 | -8.2 ± 8.78 |
Change from baseline in participant-reported HRQoL and health status as assessed by SF-36 scale score was reported. The SF-36 consists of 8 subscales (physical function, role limitations due to physical problems, pain, general health perception, vitality, social function, role limitations due to emotional problems, and mental health). Participants self-report on items in a subscale that have between 2-6 choices per item using likert-type responses (for example: none of the time, some of the time, etc.). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100; 0= worst HRQoL, 100=best HRQoL. Higher scores indicate better health status.
| Units on scale | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD |
|---|---|---|
| Physical Functioning Week 4 | 3.5 ± 7.16 | 2.2 ± 6.85 |
| Physical Functioning Week 8 | 5.4 ± 7.64 | 3.8 ± 8.19 |
| Physical Functioning Week 12 | 5.8 ± 8.29 | 4.7 ± 8.00 |
| Physical Functioning Week 16 | 6.2 ± 8.36 | 5.2 ± 8.42 |
| Physical Functioning Week 20 | 6.1 ± 8.62 | 5.1 ± 8.87 |
| Physical Functioning Week 24 | 6.2 ± 9.01 | 5.9 ± 9.23 |
| Physical Functioning Week 28 | 6.4 ± 8.68 | 6.2 ± 9.51 |
| Physical Functioning Week 32 | 6.8 ± 8.79 | 6.4 ± 9.58 |
| Role-Physical Week 4 | 5.7 ± 9.57 | 3.1 ± 9.75 |
| Role-Physical Week 8 | 7.5 ± 10.49 | 6.1 ± 11.67 |
| Role-Physical Week 12 | 8.8 ± 10.59 | 7.1 ± 11.38 |
| Role-Physical Week 16 | 10.0 ± 11.60 | 8.3 ± 12.47 |
| Role-Physical Week 20 | 10.0 ± 11.75 | 8.2 ± 12.34 |
| Role-Physical Week 24 | 10.4 ± 11.97 | 9.2 ± 12.50 |
| Role-Physical Week 28 | 10.9 ± 11.92 | 8.8 ± 12.62 |
| Role-Physical Week 32 | 11.7 ± 11.97 | 9.4 ± 12.39 |
| Body Pain Week 4 | 3.7 ± 9.05 | 2.3 ± 8.50 |
| Body Pain Week 8 | 4.5 ± 10.04 | 4.0 ± 8.85 |
| Body Pain Week 12 | 5.1 ± 9.93 | 5.3 ± 9.71 |
| Body Pain Week 16 | 5.6 ± 10.05 | 5.5 ± 10.52 |
| Body Pain Week 20 | 5.7 ± 11.14 | 6.0 ± 10.41 |
| Body Pain Week 24 | 6.2 ± 10.68 | 6.1 ± 10.64 |
| Body Pain Week 28 | 6.2 ± 11.32 | 6.3 ± 11.34 |
| Body Pain Week 32 | 6.7 ± 11.03 | 7.2 ± 11.62 |
| General Health Week 4 | 5.3 ± 7.85 | 3.3 ± 7.45 |
| General Health Week 8 | 7.2 ± 8.63 | 5.7 ± 8.50 |
| General Health Week 12 | 7.9 ± 8.79 | 6.4 ± 9.02 |
| General Health Week 16 | 8.8 ± 9.09 | 7.3 ± 9.55 |
| General Health Week 20 | 9.0 ± 9.30 | 7.2 ± 9.71 |
| General Health Week 24 | 9.5 ± 9.73 | 7.7 ± 10.05 |
| General Health Week 28 | 10.1 ± 9.71 | 8.8 ± 10.38 |
| General Health Week 32 | 10.6 ± 10.25 | 9.7 ± 10.33 |
| Vitality Week 4 | 8.7 ± 9.13 | 5.2 ± 7.75 |
| Vitality Week 8 | 11.3 ± 10.04 | 9.2 ± 9.44 |
| Vitality Week 12 | 12.4 ± 10.36 | 10.8 ± 9.79 |
| Vitality Week 16 | 13.1 ± 10.69 | 12.1 ± 9.88 |
| Vitality Week 20 | 13.2 ± 10.67 | 12.6 ± 10.64 |
| Vitality Week 24 | 13.4 ± 10.83 | 12.9 ± 11.26 |
| Vitality Week 28 | 14.2 ± 11.25 | 13.9 ± 11.19 |
| Vitality Week 32 | 15.2 ± 11.64 | 14.0 ± 11.34 |
| Social Functioning Week 4 | 7.1 ± 10.32 | 5.0 ± 8.83 |
| Social Functioning Week 8 | 11.2 ± 11.42 | 8.7 ± 9.59 |
| Social Functioning Week 12 | 12.4 ± 11.29 | 10.2 ± 10.45 |
| Social Functioning Week 16 | 13.5 ± 10.92 | 11.2 ± 11.24 |
| Social Functioning Week 20 | 13.6 ± 11.65 | 11.7 ± 10.73 |
| Social Functioning Week 24 | 14.3 ± 11.55 | 12.5 ± 11.75 |
| Social Functioning Week 28 | 15.3 ± 11.26 | 13.3 ± 11.15 |
| Social Functioning Week 32 | 16.1 ± 11.34 | 13.8 ± 11.47 |
| Role-Emotional Week 4 | 8.6 ± 9.62 | 5.3 ± 9.53 |
| Role-Emotional Week 8 | 12.7 ± 10.67 | 10.1 ± 11.30 |
| Role-Emotional Week 12 | 13.8 ± 10.70 | 12.2 ± 11.48 |
| Role-Emotional Week 16 | 15.4 ± 11.30 | 13.2 ± 12.07 |
| Role-Emotional Week 20 | 15.8 ± 11.26 | 13.4 ± 11.14 |
| Role-Emotional Week 24 | 16.0 ± 11.79 | 14.7 ± 11.71 |
| Role-Emotional Week 28 | 17.3 ± 12.44 | 15.0 ± 11.58 |
| Role-Emotional Week 32 | 18.1 ± 12.49 | 14.9 ± 12.62 |
| Mental Health Week 4 | 9.8 ± 9.77 | 6.7 ± 9.34 |
| Mental Health Week 8 | 13.5 ± 10.37 | 11.6 ± 10.78 |
| Mental Health Week 12 | 15.0 ± 10.50 | 13.3 ± 10.84 |
| Mental Health Week 16 | 16.1 ± 11.04 | 14.3 ± 11.01 |
| Mental Health Week 20 | 16.5 ± 10.90 | 14.7 ± 11.36 |
| Mental Health Week 24 | 16.6 ± 11.69 | 15.3 ± 11.45 |
| Mental Health Week 28 | 17.6 ± 11.40 | 16.5 ± 12.16 |
| Mental Health Week 32 | 18.4 ± 11.89 | 17.0 ± 12.05 |
Change from baseline in participant-reported HRQoL and health status as assessed by SF-36 domain scores at LOCF was reported. The SF-36 consists of 8 subscales (physical function, role limitations due to physical problems, pain, general health perception, vitality, social function, role limitations due to emotional problems, and mental health). Participants self-report on items in a subscale that have between 2-6 choices per item using likert-type responses (for example: none of the time, some of the time, etc.). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100; 0= worst HRQoL, 100=best HRQoL. Higher scores indicate better health status. LOCF is defined as participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.
| Units on scale | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD |
|---|---|---|
| Physical Functioning Week 8 | 5.1 ± 7.61 | 3.2 ± 8.15 |
| Physical Functioning Week 12 | 5.3 ± 8.22 | 3.9 ± 7.96 |
| Physical Functioning Week 16 | 5.6 ± 8.33 | 4.2 ± 8.27 |
| Physical Functioning Week 20 | 5.5 ± 8.63 | 4.0 ± 8.48 |
| Physical Functioning Week 24 | 5.6 ± 8.83 | 4.4 ± 8.84 |
| Physical Functioning Week 28 | 5.6 ± 8.71 | 4.5 ± 8.97 |
| Physical Functioning Week 32 | 6.0 ± 8.77 | 4.6 ± 9.05 |
| Role-Physical Week 8 | 7.4 ± 10.51 | 5.3 ± 11.50 |
| Role-Physical Week 12 | 8.3 ± 10.87 | 5.7 ± 11.31 |
| Role-Physical Week 16 | 9.3 ± 11.49 | 6.2 ± 12.23 |
| Role-Physical Week 20 | 9.1 ± 11.69 | 6.3 ± 12.09 |
| Role-Physical Week 24 | 9.2 ± 11.93 | 6.9 ± 12.48 |
| Role-Physical Week 28 | 9.4 ± 12.00 | 6.8 ± 12.36 |
| Role-Physical Week 32 | 10.2 ± 12.21 | 7.2 ± 12.29 |
| Body Pain Week 8 | 4.4 ± 9.84 | 3.5 ± 8.79 |
| Body Pain Week 12 | 4.8 ± 9.99 | 4.2 ± 9.51 |
| Body Pain Week 16 | 5.2 ± 10.14 | 4.3 ± 10.02 |
| Body Pain Week 20 | 5.2 ± 10.85 | 4.5 ± 10.05 |
| Body Pain Week 24 | 5.6 ± 10.45 | 4.4 ± 10.26 |
| Body Pain Week 28 | 5.4 ± 11.01 | 4.5 ± 10.78 |
| Body Pain Week 32 | 6.0 ± 10.93 | 5.0 ± 11.10 |
| General Health Week 8 | 6.9 ± 8.85 | 4.9 ± 8.19 |
| General Health Week 12 | 7.4 ± 9.19 | 5.1 ± 8.68 |
| General Health Week 16 | 8.0 ± 9.41 | 5.6 ± 9.20 |
| General Health Week 20 | 8.1 ± 9.60 | 5.5 ± 9.37 |
| General Health Week 24 | 8.2 ± 10.08 | 5.6 ± 9.57 |
| General Health Week 28 | 8.6 ± 10.19 | 6.1 ± 10.01 |
| General Health Week 32 | 9.2 ± 10.78 | 6.7 ± 10.18 |
| Vitality Week 8 | 11.1 ± 10.08 | 7.8 ± 9.46 |
| Vitality Week 12 | 11.7 ± 10.48 | 8.7 ± 9.98 |
| Vitality Week 16 | 12.3 ± 10.81 | 9.5 ± 10.26 |
| Vitality Week 20 | 12.3 ± 10.94 | 9.6 ± 10.77 |
| Vitality Week 24 | 12.2 ± 11.04 | 9.6 ± 11.34 |
| Vitality Week 28 | 12.8 ± 11.43 | 10.1 ± 11.53 |
| Vitality Week 32 | 13.8 ± 11.99 | 10.4 ± 11.65 |
| Social Functioning Week 8 | 10.7 ± 11.31 | 7.6 ± 9.72 |
| Social Functioning Week 12 | 11.4 ± 11.29 | 8.6 ± 10.47 |
| Social Functioning Week 16 | 12.2 ± 11.24 | 9.0 ± 11.22 |
| Social Functioning Week 20 | 12.3 ± 11.91 | 9.1 ± 10.92 |
| Social Functioning Week 24 | 12.7 ± 11.81 | 9.5 ± 11.63 |
| Social Functioning Week 28 | 13.0 ± 12.09 | 9.8 ± 11.49 |
| Social Functioning Week 32 | 14.0 ± 12.35 | 10.3 ± 11.71 |
| Role-Emotional Week 8 | 12.0 ± 10.75 | 8.6 ± 11.30 |
| Role-Emotional Week 12 | 12.7 ± 10.89 | 9.8 ± 11.82 |
| Role-Emotional Week 16 | 14.2 ± 11.53 | 10.3 ± 12.32 |
| Role-Emotional Week 20 | 14.3 ± 11.77 | 10.4 ± 11.67 |
| Role-Emotional Week 24 | 14.3 ± 12.15 | 11.2 ± 12.22 |
| Role-Emotional Week 28 | 15.2 ± 12.91 | 11.2 ± 12.30 |
| Role-Emotional Week 32 | 16.0 ± 13.16 | 11.2 ± 12.96 |
| Mental Health Week 8 | 12.9 ± 10.76 | 9.8 ± 11.04 |
| Mental Health Week 12 | 14.0 ± 11.09 | 10.6 ± 11.44 |
| Mental Health Week 16 | 14.7 ± 11.63 | 10.9 ± 11.85 |
| Mental Health Week 20 | 15.0 ± 11.64 | 11.2 ± 12.07 |
| Mental Health Week 24 | 14.8 ± 12.24 | 11.5 ± 12.23 |
| Mental Health Week 28 | 15.5 ± 12.35 | 12.2 ± 13.01 |
| Mental Health Week 32 | 16.3 ± 12.90 | 12.6 ± 13.08 |
Change from baseline in participant-reported quality of life as assessed by QLDS total score was reported. The QLDS is a disease-specific validated PRO measure which assesses the impact that depression has on a participant's quality of life. It is a 34-item self-rated questionnaire which consists of dichotomous response questions, with the response being either True/Not True. Each statement on the QLDS is given a score of "1" or "0". A score of "1" is indicative of adverse quality of life. All item scores are summed to give a total score that ranges from 0 (good quality of life) to 34 (very poor quality of life). A higher score indicates a more severe condition.
| Units on Scale | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD |
|---|---|---|
| Week 4 | -8.9 ± 8.83 | -5.6 ± 7.43 |
| Week 8 | -12.0 ± 9.36 | -9.1 ± 9.31 |
| Week 12 | -13.5 ± 9.30 | -10.9 ± 9.52 |
| Week 16 | -14.2 ± 9.39 | -11.6 ± 9.39 |
| Week 20 | -14.3 ± 9.50 | -12.1 ± 9.74 |
| Week 24 | -14.9 ± 9.44 | -12.8 ± 9.64 |
| Week 28 | -15.6 ± 9.42 | -13.7 ± 9.51 |
| Week 32 | -16.0 ± 9.55 | -14.2 ± 9.96 |
Change from baseline in participant-reported quality of life as assessed by QLDS total score at LOCF was reported. The QLDS is a disease-specific validated PRO measure which assesses the impact that depression has on a participant's quality of life. It is a 34-item self-rated questionnaire which consists of dichotomous response questions, with the response being either True/Not True. Each statement on the QLDS is given a score of "1" or "0". A score of "1" is indicative of adverse quality of life. All item scores are summed to give a total score that ranges from 0 (good quality of life) to 34 (very poor quality of life). A higher score indicates a more severe condition. LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.
| Units on Scale | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD |
|---|---|---|
| Week 4 | -8.9 ± 8.83 | -5.6 ± 7.43 |
| Week 8 | -11.3 ± 9.59 | -8.1 ± 9.22 |
| Week 12 | -12.3 ± 9.73 | -9.0 ± 9.62 |
| Week 16 | -13.0 ± 9.86 | -9.3 ± 9.80 |
| Week 20 | -13.0 ± 9.93 | -9.5 ± 10.02 |
| Week 24 | -13.3 ± 9.98 | -9.8 ± 10.18 |
| Week 28 | -13.6 ± 10.06 | -10.3 ± 10.26 |
| Week 32 | -14.1 ± 10.29 | -10.5 ± 10.59 |
Change from baseline in participant-reported health-related quality of Life as assessed by EQ-5D-5L score: health status index was reported. The EQ-5D-5L is a standardized 2-part instrument used to measure health outcomes, primarily designed for self-completion by respondents. It consists of the EQ-5D-5L descriptive system and the EQ Visual Analogue Scale (EQ-VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions is divided into 5 levels of perceived problems (level 1 = no problem, level 2 = slight problems, level 3 = moderate problems, level 4 = severe problems, level 5 = extreme problems). The participant selects an answer for each of the 5 dimensions considering the response that best matches his or her health "today." Responses were used to generate health status index which ranges from 0 (dead) and 1 (full health), a lower score indicates worse health.
| Units on Scale | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD |
|---|---|---|
| Week 4 | 0.177 ± 0.2354 | 0.124 ± 0.2280 |
| Week 8 | 0.234 ± 0.2655 | 0.206 ± 0.2463 |
| Week 12 | 0.276 ± 0.2405 | 0.227 ± 0.2367 |
| Week 16 | 0.284 ± 0.2445 | 0.232 ± 0.2431 |
| Week 20 | 0.294 ± 0.2399 | 0.238 ± 0.2423 |
| Week 24 | 0.297 ± 0.2498 | 0.259 ± 0.2489 |
| Week 28 | 0.303 ± 0.2584 | 0.262 ± 0.2492 |
| Week 32 | 0.317 ± 0.2636 | 0.279 ± 0.2581 |
Change from baseline in participant-reported health-related quality of Life as assessed by EQ-5D-5L score: health status index at LOCF was reported. The EQ-5D-5L is a standardized 2-part instrument used to measure health outcomes, primarily designed for self-completion by respondents. It consists of the EQ-5D-5L descriptive system and the EQ-VAS. The EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 dimensions is divided into 5 levels of perceived problems (level 1 = no problem, level 2 = slight problems, level 3 = moderate problems, level 4 = severe problems, level 5 = extreme problems). The participant selects an answer for each of the 5 dimensions considering the response that best matches his or her health "today." LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.
| Units on Scale | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD |
|---|---|---|
| Week 4 | 0.177 ± 0.2354 | 0.124 ± 0.2280 |
| Week 8 | 0.221 ± 0.2681 | 0.175 ± 0.2510 |
| Week 12 | 0.247 ± 0.2552 | 0.187 ± 0.2523 |
| Week 16 | 0.255 ± 0.2580 | 0.188 ± 0.2595 |
| Week 20 | 0.261 ± 0.2600 | 0.187 ± 0.2590 |
| Week 24 | 0.264 ± 0.2627 | 0.196 ± 0.2671 |
| Week 28 | 0.266 ± 0.2739 | 0.195 ± 0.2664 |
| Week 32 | 0.280 ± 0.2806 | 0.207 ± 0.2739 |
Change from baseline in participant-reported health status as assessed by EQ-5D-5L Score: VAS was reported. The EQ-5D-5L is a standardized 2-part instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. It essentially consists of the EQ-5D-5L descriptive system and the EQ-VAS. EQ-VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Positive change in score indicates improvement.
| Units on Scale | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD |
|---|---|---|
| Week 4 | 13.3 ± 18.43 | 9.7 ± 17.83 |
| Week 8 | 18.9 ± 19.84 | 16.1 ± 19.64 |
| Week 12 | 20.9 ± 20.98 | 17.2 ± 20.73 |
| Week 16 | 21.9 ± 20.14 | 20.2 ± 22.14 |
| Week 20 | 22.3 ± 21.20 | 19.6 ± 21.59 |
| Week 24 | 23.6 ± 20.95 | 21.8 ± 21.60 |
| Week 28 | 25.2 ± 20.95 | 23.2 ± 22.11 |
| Week 32 | 24.9 ± 21.65 | 24.5 ± 22.64 |
Change from baseline in participant-reported health status as assessed by EQ-5D-5L score: VAS at LOCF was reported. The EQ-5D-5L is a standardized 2-part instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. It essentially consists of the EQ-5D-5L descriptive system and the EQ-VAS. EQ-VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Positive change in score indicates improvement. LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.
| Units on Scale | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD |
|---|---|---|
| Week 4 | 13.3 ± 18.43 | 9.7 ± 17.83 |
| Week 8 | 18.2 ± 19.94 | 14.0 ± 20.42 |
| Week 12 | 19.4 ± 21.04 | 14.4 ± 21.19 |
| Week 16 | 20.2 ± 20.37 | 16.1 ± 22.42 |
| Week 20 | 20.4 ± 21.34 | 15.4 ± 22.19 |
| Week 24 | 21.3 ± 21.34 | 16.9 ± 22.64 |
| Week 28 | 21.9 ± 21.78 | 17.3 ± 23.10 |
| Week 32 | 22.3 ± 22.47 | 18.0 ± 23.59 |
Change from baseline in participant-reported work productivity as assessed by WPAI: depression questionnaire was reported. The WPAI-D questionnaire is a validated short instrument that assesses impairment in work and other regular activities over the past 7 days. The WPAI yields four types of scores: (a) Absenteeism (work time missed); (b) Presenteeism (impairment at work / reduced on-the-job effectiveness); (c) Work productivity loss (overall work impairment / absenteeism plus presenteeism); (d) Activity Impairment. The first three scores were derived only for respondents who were working (should be missing for non-working), but the last score was applicable for all respondents. Each score ranges from 0 to 100 with higher scores indicating greater impairment and less productivity.
| Units on scale | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD |
|---|---|---|
| Absenteeism Week 4 | -11.95 ± 20.745 | -8.37 ± 25.790 |
| Absenteeism Week 8 | -19.02 ± 30.205 | -13.62 ± 31.059 |
| Absenteeism Week 12 | -21.87 ± 34.711 | -17.25 ± 31.340 |
| Absenteeism Week 16 | -22.85 ± 33.023 | -14.24 ± 37.823 |
| Absenteeism Week 20 | -27.88 ± 32.107 | -18.70 ± 35.310 |
| Absenteeism Week 24 | -26.83 ± 32.909 | -21.03 ± 34.459 |
| Absenteeism Week 28 | -27.16 ± 35.825 | -17.90 ± 31.254 |
| Absenteeism Week 32 | -28.90 ± 32.066 | -16.68 ± 29.394 |
| Presenteeism Week 4 | -21.75 ± 25.558 | -9.13 ± 21.948 |
| Presenteeism Week 8 | -31.70 ± 25.144 | -16.86 ± 27.140 |
| Presenteeism Week 12 | -35.46 ± 27.998 | -23.22 ± 29.942 |
| Presenteeism Week 16 | -36.96 ± 28.556 | -24.50 ± 31.898 |
| Presenteeism Week 20 | -39.80 ± 26.263 | -26.34 ± 33.389 |
| Presenteeism Week 24 | -42.83 ± 27.332 | -31.60 ± 30.922 |
| Presenteeism Week 28 | -43.00 ± 28.762 | -33.29 ± 34.445 |
| Presenteeism Week 32 | -47.58 ± 26.691 | -33.88 ± 33.621 |
| Work productivity loss Week 4 | -20.94 ± 25.759 | -9.46 ± 23.374 |
| Work productivity loss Week 8 | -32.91 ± 26.244 | -18.21 ± 29.156 |
| Work productivity loss Week 12 | -36.68 ± 29.247 | -25.62 ± 35.135 |
| Work productivity loss Week 16 | -38.13 ± 30.490 | -24.50 ± 34.089 |
| Work productivity loss Week 20 | -41.11 ± 28.643 | -26.57 ± 32.885 |
| Work productivity loss Week 24 | -45.31 ± 29.000 | -30.63 ± 34.087 |
| Work productivity loss Week 28 | -44.40 ± 32.098 | -32.61 ± 33.836 |
| Work productivity loss Week 32 | -50.20 ± 29.176 | -35.48 ± 35.915 |
| Activity Impairment Week 4 | -20.29 ± 23.702 | -13.43 ± 20.846 |
| Activity Impairment Week 8 | -30.31 ± 27.410 | -24.25 ± 24.187 |
| Activity Impairment Week 12 | -33.96 ± 27.218 | -28.28 ± 25.555 |
| Activity Impairment Week 16 | -35.07 ± 27.291 | -30.95 ± 27.444 |
| Activity Impairment Week 20 | -33.88 ± 28.770 | -30.93 ± 27.698 |
| Activity Impairment Week 24 | -36.69 ± 29.742 | -36.84 ± 27.000 |
| Activity Impairment Week 28 | -40.00 ± 29.828 | -37.62 ± 28.500 |
| Activity Impairment Week 32 | -41.92 ± 30.299 | -39.59 ± 27.190 |
Change from baseline in participant-reported work productivity as assessed by WPAI: depression questionnaire at LOCF was reported. The WPAI-D questionnaire is a validated short instrument that assesses impairment in work and other regular activities over the past 7 days. The WPAI yields four types of scores: (a) Absenteeism (work time missed); (b) Presenteeism (impairment at work / reduced on-the-job effectiveness); (c) Work productivity loss (overall work impairment / absenteeism plus presenteeism); (d) Activity Impairment. The first three scores were derived only for respondents who were working (should be missing for non-working), but the last score was applicable for all respondents. Each score ranges from 0 to 100 with higher scores indicating greater impairment and less productivity. LOCF is defined as the participants who had a missing value or who stopped treatment at a specific time point had their last non-missing value carried forward.
| Units on scale | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD |
|---|---|---|
| Absenteeism Week 4 | -11.95 ± 20.745 | -8.37 ± 25.790 |
| Absenteeism Week 8 | -18.28 ± 29.417 | -12.38 ± 30.369 |
| Absenteeism Week 12 | -20.23 ± 33.590 | -15.17 ± 31.835 |
| Absenteeism Week 16 | -21.35 ± 31.806 | -14.14 ± 37.534 |
| Absenteeism Week 20 | -25.45 ± 31.628 | -16.04 ± 37.769 |
| Absenteeism Week 24 | -24.41 ± 32.403 | -16.28 ± 37.672 |
| Absenteeism Week 28 | -23.88 ± 34.623 | -14.14 ± 35.849 |
| Absenteeism Week 32 | -26.10 ± 31.903 | -13.90 ± 36.104 |
| Presenteeism Week 4 | -21.75 ± 25.558 | -9.13 ± 21.948 |
| Presenteeism Week 8 | -29.45 ± 26.437 | -14.84 ± 27.067 |
| Presenteeism Week 12 | -33.57 ± 28.745 | -17.44 ± 29.997 |
| Presenteeism Week 16 | -35.00 ± 29.075 | -19.84 ± 31.322 |
| Presenteeism Week 20 | -36.08 ± 28.598 | -21.41 ± 32.862 |
| Presenteeism Week 24 | -36.87 ± 29.641 | -22.19 ± 32.189 |
| Presenteeism Week 28 | -37.40 ± 30.924 | -23.83 ± 34.757 |
| Presenteeism Week 32 | -40.53 ± 30.700 | -23.44 ± 35.526 |
| Work productivity loss Week 4 | -20.94 ± 25.759 | -9.46 ± 23.374 |
| Work productivity loss Week 8 | -30.59 ± 26.789 | -15.35 ± 30.059 |
| Work productivity loss Week 12 | -34.46 ± 29.333 | -19.27 ± 33.905 |
| Work productivity loss Week 16 | -36.35 ± 30.531 | -20.75 ± 33.545 |
| Work productivity loss Week 20 | -37.59 ± 30.354 | -22.58 ± 34.117 |
| Work productivity loss Week 24 | -39.02 ± 31.482 | -22.54 ± 34.635 |
| Work productivity loss Week 28 | -39.09 ± 33.271 | -23.85 ± 35.152 |
| Work productivity loss Week 32 | -43.42 ± 32.638 | -24.89 ± 37.870 |
| Activity Impairment Week 4 | -20.29 ± 23.702 | -13.43 ± 20.846 |
| Activity Impairment Week 8 | -28.84 ± 27.412 | -20.39 ± 24.599 |
| Activity Impairment Week 12 | -31.10 ± 27.778 | -22.81 ± 26.264 |
| Activity Impairment Week 16 | -31.84 ± 28.413 | -23.68 ± 28.014 |
| Activity Impairment Week 20 | -30.84 ± 29.983 | -23.62 ± 28.185 |
| Activity Impairment Week 24 | -32.45 ± 31.207 | -26.71 ± 28.821 |
| Activity Impairment Week 28 | -34.87 ± 31.804 | -27.07 ± 29.965 |
| Activity Impairment Week 32 | -36.65 ± 32.357 | -28.40 ± 29.930 |
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. TEAEs were those events if they started after administration of the first dose until 14 days after the last dose of study medication for other TEAEs except serious; and first dose until 30 days after the last dose of study medication for serious TEAEs.
| Participants | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 307 | 262 |
Number of participants with TEAEs of special interest were reported. It included significant TEAEs that were judged to be of special interest because of clinical importance, known or suspected class effects, or based on nonclinical signals. Events such as sedation, depersonalization/derealization disorder, depression suicidal, aggression, allergic cystitis, cholestasis and jaundice of hepatic origin, and many more were considered as TEAEs of special interest.
| Participants | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD |
|---|---|---|
| Number of Participants With TEAEs of Special Interest | 223 | 140 |
Number of participants with suicidal ideation or behavior as assessed by C-SSRS score was reported. The C-SSRS is an assessment tool that evaluates suicidal ideation and behavior. Suicidal ideation consists of 5 items: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intention to act, active suicidal ideation with some intent to act without specific plan, and active suicidal ideation with specific plan and intent. Suicidal behavior consists of 5 items: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt (non-fatal), and completed suicide. The maximum score (from the 10 categories) assigned for each participant was summarized into one of three broad categories: No suicidal ideation or behavior (0), Suicidal ideation (1 - 5), Suicidal behavior (6 - 10). Total score ranges from 1 to 10. Higher scores indicate more severe suicidal ideation and behavior.
| Participants | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD |
|---|---|---|
| Suicidal Ideation Week 1 | 22 | 25 |
| Suicidal Behavior Week 1 | 0 | 0 |
| Suicidal Ideation Week 2 | 21 | 32 |
| Suicidal Behavior Week 2 | 0 | 1 |
| Suicidal Ideation Week 3 | 19 | 17 |
| Suicidal Behavior Week 3 | 0 | 0 |
| Suicidal Ideation Week 4 | 22 | 27 |
| Suicidal Behavior Week 4 | 0 | 0 |
| Suicidal Ideation Week 8 | 21 | 18 |
| Suicidal Behavior Week 8 | 0 | 0 |
| Suicidal Ideation Week 12 | 13 | 14 |
| Suicidal Behavior Week 12 | 0 | 0 |
| Suicidal Ideation Week 16 | 12 | 12 |
| Suicidal Behavior Week 16 | 1 | 1 |
| Suicidal Ideation Week 20 | 15 | 14 |
| Suicidal Behavior Week 20 | 0 | 0 |
| Suicidal Ideation Week 24 | 14 | 9 |
| Suicidal Behavior Week 24 | 0 | 0 |
| Suicidal Ideation Week 28 | 8 | 5 |
| Suicidal Behavior Week 28 | 0 | 0 |
| Suicidal Ideation Week 32 | 7 | 4 |
| Suicidal Behavior Week 32 | 0 | 1 |
Collected over All-cause mortality and serious adverse events: until 30 days after last dose (up to Week 35); other AEs: until 14 days after last dose (up to Week 33). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Esketamine Nasal Spray + Oral Antidepressant (AD) | 1/334 (0.3%) | 19/334 (5.7%) | 289/334 (86.5%) |
| Quetiapine Extended Release (XR) + Oral AD | 1/336 (0.3%) | 17/336 (5.1%) | 216/336 (64.3%) |
| Event | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD |
|---|---|---|
| DepressionPsychiatric disorders | 2/334 | 3/336 |
| Suicidal ideationPsychiatric disorders | 1/334 | 3/336 |
| Somatic symptom disorderPsychiatric disorders | 2/334 | 0/336 |
| Suicide attemptPsychiatric disorders | 2/334 | 1/336 |
| AnxietyPsychiatric disorders | 0/334 | 2/336 |
| Acute coronary syndromeCardiac disorders | 1/334 | 0/336 |
| Atrial fibrillationCardiac disorders | 1/334 | 0/336 |
| Retinal detachmentEye disorders | 1/334 | 0/336 |
| PancreatitisGastrointestinal disorders | 1/334 | 0/336 |
| DeathGeneral disorders | 1/334 | 0/336 |
| Event | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD |
|---|---|---|
| DizzinessNervous system disorders | 156/334 | 28/336 |
| NauseaGastrointestinal disorders | 98/334 | 12/336 |
| DissociationPsychiatric disorders | 94/334 | 2/336 |
| HeadacheNervous system disorders | 82/334 | 43/336 |
| SomnolenceNervous system disorders | 50/334 | 78/336 |
| VertigoEar and labyrinth disorders | 63/334 | 3/336 |
| Weight increasedInvestigations | 9/334 | 42/336 |
| DysgeusiaNervous system disorders | 40/334 | 1/336 |
| ParaesthesiaNervous system disorders | 37/334 | 2/336 |
| VomitingGastrointestinal disorders | 36/334 | 5/336 |
| Age, Continuous(years) | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD | Total |
|---|---|---|---|
| Mean | 44.3 ± 13.6 | 45.7 ± 13.38 | 45 ± 13.5 |
| Sex: Female, Male(Participants) | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD | Total |
|---|---|---|---|
| Female | 225 | 222 | 447 |
| Male | 111 | 118 | 229 |
| Race (NIH/OMB)(Participants) | Esketamine Nasal Spray + Oral Antidepressant (AD) | Quetiapine Extended Release (XR) + Oral AD | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 9 | 10 | 19 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 7 | 12 |
| White | 137 | 152 | 289 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 185 | 171 | 356 |
Showing the first 100 of 171 sites across 24 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Aug 2020 to primary completion in Jan 2022, 16 months.
Results were first posted in Feb 2023, 1 year after primary completion.
Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 16 months is below that.
Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esketamine
Janssen-Cilag International NV →